Table 1.
Presenting features of patients with lupus nephritis.
| Features | All patients (n=163) | Class III and IV (n=122) |
|---|---|---|
| Gender* | ||
| Female | 138 (85%) | 102 (84%) |
| Male: | 25 (15%) | 20(16%) |
| Race* | ||
| African-American: | 78 (48%) | 56 (46%) |
| Hispanics | 68 (42%) | 55 (45%) |
| Caucasians | 12 (7%) | 8 (7%) |
| Others: | 5 (3%) | 3 (2%) |
| Age (Years) at LN diagnosis | 32.3±11.4 | 31.4±11.2 |
| Initial Presentation* | ||
| LN | 23 (14%) | 16 (13%) |
| LN with others | 41 (25%) | 35 (29%) |
| Others | 99 (61%) | 71(58%) |
| Hypertension* | 112 (69%) | 91 (75%) |
| Anemia* | 67 (45%) | 55 (50%) |
| Proteinuria (mg/g) | 3816.8±3459.6 | 4043.0±3395.7 |
| Creatinine (mg/dl) | 1.6±1.5 | 1.7±1.6 |
| Number of co morbidities* | ||
| 0 | 21 (13%) | 16 (13%) |
| 1 | 31 (19%) | 24 (20%) |
| 2 or more | 111 (68%) | 82 (67%) |
| ISN/RPS class of LN* | ||
| II | 18 (11%) | |
| III | 59 (36%) | 59 (48%) |
| IV | 63 (39%) | 63 (52%) |
| V | 22 (13.5%) | |
| VI | 1 (1%) | |
| Treatment induction* | ||
| Mycophenolate | 54 (33%) | 38 (31%) |
| Cyclophosphamide | 77 (47%) | 76 (62%) |
| None | 12 (7%) | 3 (2%) |
| OTHER | 20 (12%) | 5 (4%) |
| Maintenance* | ||
| Mycophenolate | 78 (48%) | 63 (52%) |
| Cyclophosphamide | 34 (21%) | 34 (28%) |
| None | 27 (17%) | 14 (11%) |
| OTHER | 24 (15%) | 11 (9%) |
| Response* | ||
| CR | 62 (38%) | 41 (34%) |
| PR | 23 (14%) | 18 (15%) |
| No response | 37 (23%) | 24 (20%) |
| ESRD | 37 (23%) | 36 (30%) |
| Death | 4 (2%) | 3 (2%) |
| Follow up (months) | 37.5±28.3 | 36.0±27.2 |
| Non adherence* | 34 (21%) | 30 (25%) |
| Relapses* | 32 (20%) | 30 (25%) |
LN: Lupus, nephritis, ISN/RPS (International Society of Nephrology/ Renal Pathology Society),
*
Indicates that the corresponding values for that feature will be expressed as the number (percent) of patients in each column.